Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2011

View Archived Issues

Lupeol curbs growth of androgen-dependent and castration-resistant prostate cancer cells

New nonelectrophilic reference agonist discovered to assess TRPA1 channel pharmacology

Pilot trial evaluates Flebogamma DIF in patients with Alzheimer's disease

Novel protein Wnt signaling pathway inhibitors synthesized at Epitherix

Merck & Co. claims new muscarinic acetylcholine M1 receptor modulators

Researchers at Sanofi present novel kinesin-like protein KIF11 inhibitors

SuppreMol and Protagen to identify therapy-related biomarkers in patients with SLE

Takeda patents new melanin-concentrating hormone MCH1 receptor antagonists

Akorn announces partnership with Aciex Therapeutics

Novel series of histamine H3 receptor antagonists presented

Novartis enrolls patients in phase II BPS-804 trials

Korean company prepares new AMPK activators

Merck & Co. and Serum Institute of India to develop pneumococcal conjugate vaccine

Zoely is approved in the E.U.

Interim data reported from phase I/II trial of ProSavin

Agreement reached on design of phase III Rhucin study in hereditary angioedema

New serum biomarker to predict response to IFN-beta therapy in MS

FDA accepts ruxolitinib NDA filing for myelofibrosis

FDA issues warning regarding chronic high-dose fluconazole therapy

Phase III ragweed allergy immunotherapy tablet studies meet primary endpoints

Sanofi recruits patients for phase II SAR-279356 trial

NPS Pharmaceuticals and GSK form new calcilytics agreement

Enrollment begins in phase IIb/III study of masitinib in rheumatoid arthritis

Thrombotech begins enrollment in phase IIa trial of lead product in ischemic stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...